CN Patent

CN111315378A — 包含lsz102和瑞博西尼的药物组合

Assigned to Novartis AG · Expires 2020-06-19 · 6y expired

What this patent protects

本发明涉及包含LSZ102和瑞博西尼的药物组合；包含所述药物组合的药物组合物；以及在治疗或预防其中雌激素受体的降解与CDK4/6抑制组合是有益的病症中、例如在治疗癌症中使用此类组合和组合物的方法。

USPTO Abstract

本发明涉及包含LSZ102和瑞博西尼的药物组合；包含所述药物组合的药物组合物；以及在治疗或预防其中雌激素受体的降解与CDK4/6抑制组合是有益的病症中、例如在治疗癌症中使用此类组合和组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111315378A
Jurisdiction
CN
Classification
—
Expires
2020-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.